Legis Daily

MVP Act

USA117th CongressHR-7389| House 
| Updated: 4/5/2022
Kurt Schrader

Kurt Schrader

Democratic Representative

Oregon

Cosponsors (4)
Markwayne Mullin (Republican)Brett Guthrie (Republican)Jake Auchincloss (Democratic)John Joyce (Republican)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Medicaid VBPs for Patients Act or the MVP Act This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. ( Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.) The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-1339
MVP Act of 2019
Apr 4, 2022
Introduced in House
Apr 4, 2022
Referred to the House Committee on Energy and Commerce.
Apr 5, 2022
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-1339
    MVP Act of 2019


  • April 4, 2022
    Introduced in House


  • April 4, 2022
    Referred to the House Committee on Energy and Commerce.


  • April 5, 2022
    Referred to the Subcommittee on Health.

Health

MVP Act

USA117th CongressHR-7389| House 
| Updated: 4/5/2022
Medicaid VBPs for Patients Act or the MVP Act This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. ( Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.) The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-1339
MVP Act of 2019
Apr 4, 2022
Introduced in House
Apr 4, 2022
Referred to the House Committee on Energy and Commerce.
Apr 5, 2022
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-1339
    MVP Act of 2019


  • April 4, 2022
    Introduced in House


  • April 4, 2022
    Referred to the House Committee on Energy and Commerce.


  • April 5, 2022
    Referred to the Subcommittee on Health.
Kurt Schrader

Kurt Schrader

Democratic Representative

Oregon

Cosponsors (4)
Markwayne Mullin (Republican)Brett Guthrie (Republican)Jake Auchincloss (Democratic)John Joyce (Republican)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted